<DOC>
	<DOCNO>NCT02175654</DOCNO>
	<brief_summary>The purpose study assess efficacy single-agent regorafenib second-line treatment metastatic colorectal cancer RAS BRAF mutation previously treat FOLFOXIRI plus bevacizumab term progression-free survival 6 month .</brief_summary>
	<brief_title>Regorafenib Single Agent Patients With Metastatic Colorectal Cancer ( mCRC ) With Any RAS BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Signing informed consent form . 2 . The patient must able understand information state expressly desire take part study . 3 . Age ≥ 18 year . 4 . Histologically cytologically document adenocarcinoma colon rectum . 5 . Patients metastatic colorectal cancer ( stage IV ) RAS BRAF mutation . 6 . To receive first_line treatment bevacizumab combination chemotherapy three drug 5FU/leucovorin ( LV ) , irinotecan oxaliplatin ( FOLFOXIRI ) , radiological progression disease first_line treatment , radiological progression disease within period ≤ 6 month last dose firstline treatment , discontinue part first_line treatment due toxicity radiological progression disease within period ≤ 6 month last dose firstline treatment . The patient receive least one cycle bevacizumab combination FOLFOXIRI + bevacizumab part first_line treatment . Patients may receive fluoropyrimidine_based adjuvant treatment without oxaliplatin . 7 . Existence least one measurable unidimensional lesion use CT MRI base Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , version 1.1 8 . Overall Eastern Cooperative Oncology Group ( ECOG ) performance ≤1 . 9 . Patient 's commitment compliance oral medication throughout duration study 10 . Life expectancy least 3 month 11 . Adequate bone marrow , renal hepatic function , define : Neutrophils ≥ 1500/mm3 Platelets ≥100,000/mm3 Haemoglobin ≥ 9,0 g/dL Serum Creatinine ≤ 1.5 x LSN Bilirubin level ≤ 1.5 x LSN AST ALT level ≤ 2.5 x ULN ( liver metastasis &lt; 5 x ULN ) 1 . Prior treatment regorafenib . 2 . Assignment prior treatment study . Patients permanently withdraw participation study treatment allow return . 3 . Prior concurrent presence another neoplastic disease different term tumour site histology colorectal cancer 5 year prior inclusion patient study , except situ cervical cancer , superficial bladder carcinoma [ Ta ( noninvasive ) , Tis ( carcinoma situ ) T1 ( tumour invades lamina propria ) ] nonmelanoma skin tumour . 4 . Presence history brain metastasis meningeal tumour . 5 . Major surgery , open biopsy traumatic injury within 28 day prior start patient treatment study medication . 6 . Extendedfield radiotherapy within 4 week prior inclusion limitedfield radiotherapy previous 2 week . Patients must recover treatmentrelated toxicity . 7 . Pregnant breastfeed woman . Women childbearing age must use adequate contraception . Women childbearing age must negative pregnancy test within 7 day prior start study medication . 8 . Women childbearing age men wish take part study must agree use adequate contraception signing informed consent least 3 month stop study medication . The investigator person designated ensure advise contraceptive method use . Appropriate contraceptive method include abstinence , oral contraceptive , transdermal patch injection sustainedrelease progestin ( start least 4 week administration IMP ) , doublebarrier method : condom female condom ( diaphragm cervical/vaginal condom ) plus spermicide , intrauterine device ( IUD ) , intrauterine system , implant vaginal ring ( place least 4 week administration IMP ) male partner sterilisation ( vasectomy documentation azoospermia ) prior inclusion woman trial woman 's sexual partner . 9 . Active congestive heart failure class 2 high New York Heart Association ( NYHA ) scale . 10 . Unstable angina ( angina symptom rest ) , new_onset angina ( appear past 3 month ) acute myocardial infarction occur 6 month prior start study medication . 11 . Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin would allow concomitant medication patient ) . 12 . Uncontrolled hypertension ( systolic blood pressure &gt; 150 mmHg diastolic blood pressure &gt; 90 mmHg ) despite proper medical management . 13 . Patients phaeochromocytoma . 14 . Pleural effusion ascites cause breathe difficulty ( dyspnoea grade ≥ 2 CTC ) . 15 . Venous arterial thromboembolism embolic event cerebrovascular accident ( include transient ischaemic attack ) , deep vein thrombosis pulmonary thromboembolism occur 6 month prior start study medication . 16 . Active infection &gt; grade 2 base NCI CTC , v. 4.0 . 17 . Human immunodeficiency virus ( HIV ) infection . 18 . Active hepatitis B C , hepatitis B C infection require treatment antiviral drug . 19 . Patients mental disorder require medication . 20 . History organ transplant . 21 . Patients evidence history bleed diathesis . Any bleed bleeding event &gt; Common Toxicity Criteria Adverse Effects ( CTCAE ) grade 3 4 week prior start study medication . 22 . Presence unhealed wound , ulcer bone fracture . 23 . Kidney failure require haemodialysis peritoneal dialysis . 24 . Dehydration base NCI CTC criterion , version 4 , &gt; 1 . 25 . Substance abuse history medical , social psychological condition may interfere study participation compliance efficacy safety assessment plan study . 26 . Known hypersensitivity regorafenib excipients . 27 . Presence disease medical condition might interfere patient safety may compromise treatment compliance . 28 . Interstitial lung disease sign symptoms present time signing informed consent . 29 . Patients unable swallow oral medication . 30 . Persistent proteinuria &gt; grade 3 base NCI CTC , version 4.0 ( &gt; 3.5 g/24 hour ) . 31 . Intestinal malabsorption syndrome . 32 . Close personal relationship research staff , family member investigator dependent ( e.g . employee student research centre ) . 33 . Unresolved toxicity grade &gt; 1 base NCI CTC , version 4.0 ( except alopecia ) , relate previous therapy procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>RAS/BRAF mutation</keyword>
	<keyword>Regorafenib</keyword>
	<keyword>FOLFOXIRI</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>